IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to
evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP
inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors
and with ES-SCLC who develops disease progression after 1L platinum-based regimen.